Barbara Gayle Duncan is of Atea Pharmaceuticals, Inc.. Currently has a direct ownership of 62,750 shares of AVIR, which is worth approximately $228,410. The most recent transaction as insider was on Jun 20, 2025, when has been sold 29,600 shares (Common Stock) at a price of $0.0 per share, resulting in proceeds of $0. This information was disclosed in a Form 4 filing with the Securities and Exchange Commission (SEC).

Shares Held (Direct Ownership) 62.8K
89.29% 3M change
89.29% 12M change
Total Value Held $228,410

Barbara Gayle Duncan Transaction History

Date Transaction Value Shares Traded Shares Held Form
Jun 20 2025
BUY
Exercise of conversion of derivative security
-
29,600 Added 32.05%
62,750 Common Stock
Jun 16 2024
BUY
Exercise of conversion of derivative security
-
33,150 Added 50.0%
33,150 Common Stock

Also insider at

IMMU
IMMUNOMEDICS INC
FUSN
Fusion Pharmaceuticals Inc. Healthcare
OVID
Ovid Therapeutics Inc. Healthcare
JNCE
Jounce Therapeutics, Inc. Healthcare
ADAP
Adaptimmune Therapeutics PLC Healthcare
HALO
HALOZYME THERAPEUTICS, INC. Healthcare
BGD

Barbara Gayle Duncan

Boston, MA

Track Institutional and Insider Activities on AVIR

Follow Atea Pharmaceuticals, Inc. and customize your updates to receive the information that matters most to you.

Institutional Portfolio Updates

Receive a notification when an Institution or Guru buys or sells AVIR shares.

Notify only if

Insider Trading

Get notified when an Atea Pharmaceuticals, Inc. insider buys or sells AVIR shares.

Notify only if

News

Receive news related to Atea Pharmaceuticals, Inc.

Track Activities on AVIR